BioVersys raises €12.8M Series C round

7 May 2024· Basel, Switzerland· health, biotech, drug_discovery, antimicrobial_resistance, b2b

To accelerate clinical development of alpibectir for the treatment of tuberculosis and enable the further clinical development of BioVersys' portfolio, including BV100.

Investors

LeadGSK

Also participating

AMR Action FundGIBF

About BioVersys

Stage

Series C

Headquarters

Basel, Switzerland

Founded

2008

Team Size

21–50

Sectors

healthbiotechdrug_discoveryantimicrobial_resistanceb2b

http://www.bioversys.com/

Source: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHVN0ZpKDjFEY-26MV8agbAU-EQ3epr-jZNR_tQZC_Ew0szowNw7CU09GcCb9vVCLbGlgl-yvJe7SxO8m-pmG2SLUK_uxUYKfSE_Ym2zBKxHcsQAD5kM1mtfO0HgwCq_U14TfDWG0FArgR8fLWZHXw2ZGhXq-mcySnxeffg9X0o2PBh0s6enbklH1Rx__AwV63ZDmcFRerklmjV-zonQzHoO_Sk0weIuskOLW5cYHOp4SoKsD0a9VAJzcwIuyqOtj97qbRGPX4HsAK_YwopNMa_, https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeSE8S_cWESAzV7HaEu3BM4Hi8IkLd1J9QT6exCaS4JW2Z7NMi6Oex5fMZ932h3p0ayP0mt_kbwrh-ZiuE4SbTsYJyHuRmGriC8LAlSCBxUYw-HlxWwworQD7hEDqw-KTqnxqYGLKa-KFQf5qOiGwowIsxTw8fMr61284il9yZW6rR4JrHxMa4tyUqpqJKurAUm_CGWVkMiAm9_ZlFlTRvTFW1jd8-WwhFMEnLO0ARw6s=, https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF-5zDd5nCbkAT90nG3CrPCru7iXmbNgSzAb9azUjRMIdz9keBBDhJ5kvMkphzAYmWgC68hv0WRsfKKrtic76YeDXiQvWdxd35Frsvj-pw-SyWmi6rY6cBqa7ilemPA9VdXh3B4OkYtFT_284suGbe8fzy2Iocrjjf9CuitrulibEKP6Bo_2oEsTIJsn07qqfB-drYsLA5gwS_4hfhV-Quy9VdATgOQwFyBXUJbiyYnQlJwFBw==